To all:
>>Still... I think the Vertex crowd was hoping for something better, and that if there was a dose that delivered a 100% knockout, it would have been mentioned in the press release...<<
I think that this will unswer your question (if you use math):
From Vertex press release:
>>At 12 weeks, patients taking 141W94 at the highest dose, 1200mg twice daily, plus
Retrovir(R) (AZT) and Epivir(R) (3TC) had a median 2.65 log reduction in viral
load (greater than 99.8%) from baseline as compared to a 1.33 log reduction
for the control arm, Retrovir(R) and Epivir(R).<<
For comparison Sustiva (TM) PIII data:
>> In a 137-patient Phase III study of three Sustiva doses (200, 400 or
600 mg, once daily) in combination with AZT (300 mg, twice daily) and 3TC
(150 mg, twice daily), significant reductions in plasma HIV-RNA were observed.
After 16 weeks of treatment, the 25 patients who completed the study at the
600 mg dose achieved a 1.89 log10 average reduction in HIV-RNA levels out of a
possible 2.04 log10, and 88 percent of them achieved HIV-RNA levels below the
level of quantification (400 copies/mL). In addition, these patients
experienced an average CD4 cell count elevation of 157 cells/mm3.<<
mz |
